Top Markets
#1 Threshold Network Threshold Network +64.14%
#2 TENDIES TENDIES +60.80%
#3 Cash Cat Cash Cat +19.85%
#4 OSK OSK +15.90%
#5 Falcon Finance Falcon Finance +13.86%
#6 Magma Finance Magma Finance +13.63%
#7 Ape and Pepe Ape and Pepe +12.62%
#8 Kite Kite +12.56%
#9 Asteroid Shiba Asteroid Shiba +11.93%
#10 AI Analysis Token AI Analysis Token +8.48%
Coin of the day
Threshold Network Threshold Network
Configurações
Idioma
PORTUGUêS
Moeda
USD
Tema
Cellectis S.A. Cellectis S.A.

Cellectis S.A.

ALCLS
Classificação em ações #17125
Cellectis S.A., a clinical-stage biotechnology company founded in 1999 and... Cellectis S.A., a clinical-stage biotechnology company founded in 1999 and headquartered in Paris, France, concentrates on immuno-oncology. The firm engineers therapeutic solutions utilizing gene-edited T-cells, which are modified to display chimeric antigen receptors (CARs) for the specific identification and destruction of cancer cells. Its operations are divided into two principal segments: Therapeutics and Plants. The company's pipeline features several allogeneic CAR T-cell product candidates. These include UCART19, aimed at CD19-expressing hematologic malignancies such as acute lymphoblastic leukemia; ALLO-501 and ALLO-501A, developed to treat relapsed or refractory diffuse large B-cell lymphoma and follicular lymphoma; ALLO-316, targeting renal cell carcinoma; UCART123, for acute myeloid leukemia; and UCART22, addressing B-cell acute lymphoblastic leukemia. Additionally, Cellectis is advancing UCARTCS1 and ALLO-715 for the treatment of multiple myeloma. Cellectis has forged significant strategic partnerships and alliances with companies including Allogene Therapeutics, Inc., Les Laboratoires Servier, The University of Texas M.D. Anderson Cancer Center, and Iovance Biotherapeutics. It also maintains a strategic research and development collaboration with Cytovia Therapeutics, Inc.
Preço da ação
$3.56
Valor de mercado
$257.37M
Variação (1 dia)
5.26%
Variação (1 ano)
38.35%
País
FR
Negociar Cellectis S.A. (ALCLS)

Categoria

Healthcare
Histórico de preços das ações de Cellectis S.A. (ALCLS)
Preço de fecho mais alto: $3.46 em 2026-09-01

Preço de fecho mais baixo: $17.72 em 2007-02-01
Histórico de preços das ações da Cellectis S.A. de 2007 a 2026
Desempenho anual do preço das ações
Ano Desempenho
2026 (TTM) -20.49%
2025 169.48%
2024 -42.86%
2023 40.69%
2022 -74.52%
2021 -70.75%
2020 74.88%
2019 -10.96%
2018 -29.07%
2017 53.46%
2016 -41.97%
2015 106.63%
2014 307.22%
2013 -61.60%
2012 7.76%
2011 -4.53%
2010 -42.92%
2009 103.43%
2008 -44.49%
2007 0.00%
Preço das ações de empresas similares ou concorrentes
Empresa Preço da ação Variação 1a% País
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $548.15 36.70%
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $1.03K 45.33%
NL
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 $153.87 536.09%
US
CSL Limited CSL Limited
CSL Limited
CSL.AX
 $122.21 -10.03%
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 $757.71 8.20%
CH